A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Phase 3
662
about 5.5 years
18+
19 sites in CA, FL, LA +8
About this study
Researchers are testing whether pirtobrutinib, a treatment, is more effective than ibrutinib for people with CLL/SLL. The trial also tests if pirtobrutinib alone is effective in treating people with CLL/SLL who have not had previous treatment.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Ibrutinib
- 2.Take Pirtobrutinib
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
ibrutinib, pirtobrutinib
oral (Oral Tablet), oral
Primary: Percentage of Participants Achieving Complete Response (CR), Complete Remission with Incomplete Hematologic Recovery (CRi), Nodular Partial Remission (nPR) or Partial Response (PR): Overall Response Rate (ORR) Part 2, Percentage of Participants Achieving Complete Response (CR), Complete Remission with Incomplete Hematologic Recovery (Cri), Nodular Partial Remission (nPR) or Partial Response (PR): Overall Response Rate (ORR) Part 1
Secondary: Comparative Tolerability, Duration of Response (DOR), Event-Free Survival (EFS), IRC-assessed Progression-Free Survival (PFS), Investigator assessed Progression-Free Survival (PFS), Overall Survival (OS), Percentage of Participants Achieving DOR Part 2, Time to Next Treatment (TTNT)
Oncology